HELLP syndrome is a severe, life-threatening obstetric complication representing a multisystem disorder traditionally viewed as a severe variant or subset of preeclampsia 1,2,3. Acronymic for Hemolysis (H), Elevated Liver enzymes (EL), and Low Platelet count (LP), this syndrome typically develops in the third trimester of pregnancy, though up to 30 percent of cases present postpartum 2,5. The condition carries substantial risks of maternal and fetal morbidity and mortality due to multiorgan microvascular injury, consumptive coagulopathy, and hepatic infarction 3,4. Prompt clinical recognition using validated diagnostic criteria, rigorous maternal stabilization, and timely delivery remain the cornerstones of clinical management 4,5.

1. Etiology & Risk Factors

  • Preeclampsia Association: Coexists with preeclampsia in approximately 70 to 80 percent of clinical presentations; however, up to 15 to 20 percent of patients present with little to no antecedent hypertension or proteinuria 3,5.
  • Gestational Timing: Most commonly manifests between the 27th and 37th weeks of gestation, with approximately 30 percent presenting within 48 hours postpartum 5.
  • Genetic and Familial Predisposition: Demonstrates a familial tendency; patients with a personal history of HELLP syndrome face a significantly elevated recurrence risk in subsequent pregnancies 3. Complex polygenic multi-variant inheritance patterns combined with environmental factors contribute to individual susceptibility 3.
  • Maternal Demographics: Advanced maternal age, multiparity, Caucasian ethnicity, and underlying chronic medical conditions such as chronic hypertension, renal disease, and antiphospholipid syndrome increase baseline susceptibility 4.

2. Pathophysiology

The pathophysiology of HELLP syndrome centers on abnormal placentation leading to widespread maternal endothelial dysfunction, systemic vasoconstriction, and local activation of the coagulation cascade 3,4. Endothelial cell injury triggers microvascular platelet adhesion and aggregation, resulting in consumptive thrombocytopenia 4,7. Concurrently, red blood cells passing through narrowed, fibrin-rich microvasculature undergo mechanical shearing, producing schistocytes (microangiopathic hemolytic anemia) 7. Hepatic involvement is characterized by fibrin deposition within the sinusoidal spaces, leading to periportal necrosis, elevated serum transaminases, subcapsular hemorrhage, and the potential risk of catastrophic hepatic rupture 3,5.

HELLP syndrome β€” Pathophysiological Cascade & Clinical Flowchart 1 Trigger / Primary Insult Abnormal placentation and endothelial dysfunction 2 Cellular / Pathophysiological Cascade Microangiopathic activation and platelet consumption 3 Target Organ / Structural Change Hepatic sinusoidal fibrin deposition and microvascular hemolysis 4 Hallmark Clinical & Diagnostic Manifestation Schistocytosis, elevated LDH, transaminitis, and thrombocytopenia 5 Complications if Untreated & Therapeutic Target Hepatic rupture, DIC, and maternal stabilization via prompt delivery

3. Clinical Presentation & Classic Clinical Signs

  • History & Cardinal Symptoms: Patients frequently report nonspecific viral-like prodromal symptoms. The most common localized complaint is right upper quadrant (RUQ) or epigastric abdominal pain, often accompanied by severe generalized malaise, nausea, vomiting, and headache 2,3. Visual disturbances and sudden dependent edema may also be present 3.
  • Physical Examination & Named Clinical Signs: Examination often reveals RUQ or epigastric tenderness upon palpation without localized peritoneal signs. Elevated blood pressure is typical (though normotensive presentations occur), and generalized or facial edema may be apparent 3,5. Signs of petechiae or bruising due to severe thrombocytopenia can develop in advanced disease states 7.

4. Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

Diagnostic Modality / Test Expected Clinical & Radiological / Laboratory Finding
Gold-Standard InvestigationPeripheral blood smear demonstrating microangiopathic hemolytic anemia with schistocytes, helmet cells, and burr cells, paired with diagnostic serum chemistry panels 1,5.
Laboratory PanelElevated serum lactate dehydrogenase (LDH β‰₯ 600 IU/L due to hemolysis), unconjugated hyperbilirubinemia (β‰₯ 1.2 mg/dL), low haptoglobin, elevated AST and ALT (β‰₯ 2Γ— ULN), and profound thrombocytopenia (platelets < 100 Γ— 10⁹/L) 1,5. Coagulation panels may show elevated fibrin degradation products or disseminated intravascular coagulation (DIC) parameters in advanced disease.
Imaging / Radiology (X-ray, US, CT, MRI)Abdominal ultrasound or contrast-enhanced CT/MRI indicated when hepatic subcapsular hematoma or impending hepatic rupture is suspected, revealing heterogeneous liver echogenicity, fluid collections, or subcapsular hematomas.
ECG / Histopathology / ProceduralElectrocardiogram for cardiovascular monitoring during severe hypertensive crises; liver biopsy is rarely performed due to high bleeding risks associated with coagulopathy.

5. Staging, Classification & Clinical Scoring Systems

Criterion / Stage / Score Component Clinical Threshold, Points & Management Implication
Tennessee Classification System (Complete HELLP)Presence of all three criteria: Hemolysis (LDH β‰₯ 600 IU/L, schistocytes, bilirubin β‰₯ 1.2 mg/dL), Elevated Liver enzymes (AST/ALT β‰₯ 70 U/L), and Low Platelets (< 100 Γ— 10⁹/L). Requires immediate delivery planning 1,5.
Tennessee Classification System (Partial / Incomplete HELLP)Presence of only one or two elements of the triad. Carries significant maternal-fetal morbidity and mandates identical intensive surveillance and low threshold for delivery 5.
Mississippi Triple-Class System (Class 1)Nadir platelet count ≀ 50 Γ— 10⁹/L; highest risk for maternal mortality, DIC, and hemorrhagic complications. Requires aggressive platelet transfusion protocols and immediate delivery 5.
Mississippi Triple-Class System (Class 2 & 3)Class 2: Platelet nadir > 50 and ≀ 100 Γ— 10⁹/L. Class 3: Platelet nadir > 100 and ≀ 150 Γ— 10⁹/L. Managed with rigorous stabilization, corticosteroid administration, and timed delivery based on gestational age 5.

6. Differential Diagnosis

Differential Condition Distinguishing Clinical, Biochemical & Imaging Features
Thrombotic Thrombocytopenic Purpura (TTP)Markedly depressed ADAMTS13 activity (< 10%), prominent neurologic symptoms, severe microangiopathic hemolytic anemia, and profound thrombocytopenia with lesser hepatic enzyme elevation 4,7.
Hemolytic Uremic Syndrome (HUS)Characterized by prominent acute renal failure with minimal hepatic dysfunction, frequently triggered by Shiga toxin-producing bacterial infections or complement dysregulation 4,7.
Acute Fatty Liver of Pregnancy (AFLP)Presents typically in the third trimester with severe hepatocellular failure, profound hypoglycemia, marked hypofibrinogenemia, coagulopathy, and elevated ammonia levels, often without significant hemolysis 4.
Antiphospholipid Syndrome (APS) / SLE FlarePresence of circulating antiphospholipid antibodies, lupus anticoagulant, multi-organ thrombosis history, and normal or fluctuating platelet/liver parameters distinct from primary HELLP 4.

7. Management & Treatment Protocol

  • Initial Stabilization & Resuscitation: Immediate admission to a tertiary care labor and delivery unit or intensive care unit. Continuous maternal and fetal monitoring, establishment of large-bore IV access, and fluid management to avoid pulmonary edema while maintaining adequate end-organ perfusion 2,4.
  • First-Line Medical / Pharmacological Therapy (with exact adult dosing):
    • Eclampsia Prophylaxis: Intravenous Magnesium sulfate initiated with a loading dose of 4 to 6 g over 15 to 20 minutes, followed by a continuous maintenance infusion of 1 to 2 g/hour 1,2.
    • Severe Hypertension Control: IV Labetalol (initial bolus 20 mg, repeating/doubling every 10 minutes up to 80 mg max per dose) or IV/oral Nifedipine (10–20 mg PO every 30 minutes) to maintain blood pressure safely below 160/110 mmHg 1.
    • Corticosteroids: Betamethasone (12 mg IM every 24 hours for 2 doses) or Dexamethasone (6 mg IV every 12 hours for 4 doses) to promote fetal lung maturity if < 34 weeks gestation and to transiently improve maternal platelet counts and liver function 4,5.
  • Surgical / Interventional Indications: Prompt delivery is the definitive treatment regardless of gestational age if the patient is β‰₯ 34 weeks, experiences fetal distress, renal failure, suspected hepatic rupture, or progressive coagulopathy. If < 34 weeks and maternal-fetal status is stable, expectant management in a tertiary center with corticosteroid administration may be considered 4,5.

8. Complications & Prognosis

  • Maternal Complications: Disseminated intravascular coagulation (DIC), placental abruption, acute kidney injury, pulmonary edema, subcapsular hepatic hematoma, hepatic rupture, stroke, and maternal mortality 3,4,5.
  • Fetal / Neonatal Complications: Prematurity-related morbidities, intrauterine growth restriction (IUGR), fetal distress, oligohydramnios, and perinatal mortality 3,6.
  • Prognosis: Highly dependent on gestational age at onset, rapidity of diagnosis, and promptness of delivery. While maternal mortality has declined below 1 percent in specialized centers, significant morbidity remains, and patients carry a high recurrence risk in subsequent pregnancies 3,5.